17,261 trials
Metastatic Breast Cancer
Primary: Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1) — 1; 0; 0; 0 participants
Breast Neoplasms
Primary: Time to Tumor Progression (TTP) — 247; 215 days — p=0.156
Attention Deficit Hyperactivity Disorder
Primary: Sleep Duration — 609.57; 602.79 minutes — p=<.05
Precancerous Condition
Primary: Sulindac Concentration in the Nevi (Moles) — 0.51; 0 µg/g tissue
Prostate Cancer
Primary: Prostate-specific Antigen (PSA) Response Rate — 28; 30 participants
Irritable Bowel Syndrome · Diarrhea
Primary: Colonic Transit, Geometric Center at 24 Hours — 2.68; 3.30 units on a scale — p=0.22
Leukemia
Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1 participants
Breast Cancer
Primary: Disease Response (Tumor Measurements)Per RECIST Criteria v. 2000 — 11; 14; 3 participants — p=0.95
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants
Facial Wrinkles and Creases
Primary: Change in Subject Assessment of Wrinkles Compared to Baseline on Subject Wrinkle Assessment — 2; 5; 15; 11 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Any Adverse Event (AE) — 33; 34; 38 participants
Coronary Artery Chronic Total Occlusion
Primary: Technical Success — 77 percentage of CTOs
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Head and Neck Cancer
Primary: Patient Response to Treatment Measured by RECIST Criteria — 1; 18; 19; 2 participants